intensif
therapi
infant
acut
lymphoblast
leukemia
result
fewer
relaps
cost
increas
morbid
death
especi
induct
increas
nonhematolog
toxic
modern
treatment
strategi
infant
report
sever
immunodefici
persist
therapi
describ
immunodefici
classifi
acquir
primari
pid
congenit
immunodefici
defin
less
gener
sever
compar
immunodefici
sinc
also
play
crucial
role
function
macrophag
chemotherapi
known
induc
immunodefici
state
significantli
deplet
well
usual
immun
reconstitut
begin
complet
chemotherapi
children
greater
year
age
receiv
intens
chemotherapi
treatment
recoveri
complet
month
cessat
chemotherapi
addit
absolut
count
month
greater
describ
five
children
complet
treatment
infantil
soon
diagnos
persist
sever
immunodefici
vari
deplet
result
sever
infect
caus
death
four
success
hematopoiet
stem
cell
transplant
hsct
one
immun
defici
appear
secondari
therapi
report
highlight
import
consid
complic
patient
infant
post
chemotherapi
iwk
health
centr
research
ethic
board
review
manuscript
provid
letter
support
collect
data
five
infant
case
four
femal
one
male
treat
three
center
north
america
clinic
treatment
characterist
shown
tabl
none
patient
receiv
experiment
agent
hsct
initi
treatment
patient
complet
protocol
therapi
patient
develop
infect
treatment
despit
intraven
immunoglobulin
pneumocysti
prophylaxi
per
protocol
guidelin
patient
healthi
hospit
admiss
prior
diagnosi
except
patient
e
histori
urinari
tract
infect
acut
otiti
media
chronic
rhinorrhea
infect
requir
hospit
admiss
intraven
antibiot
none
patient
famili
histori
place
risk
pid
except
patient
b
parent
third
cousin
first
nation
commun
children
previous
diagnos
sever
combin
immunodefici
scid
mutat
test
neg
patient
c
normal
newborn
screen
scid
use
receptor
excis
circl
trec
assay
patient
treatment
chemotherapi
patient
mildli
sever
lymphopen
develop
recurr
persist
infect
identifi
formal
immunolog
consult
acquir
immunodefici
month
median
month
complet
chemotherapi
tabl
three
patient
receiv
addit
therapi
one
two
hsct
immunodefici
recogn
unfortun
four
patient
die
sever
infect
patient
e
success
treat
uncondit
unrel
donor
hsct
describ
first
report
persist
immunodefici
vari
deplet
patient
infant
follow
modern
intens
chemotherapi
patient
cohort
remain
mildli
sever
lymphopen
flow
cytometri
demonstr
extrem
low
popul
consist
sever
immunodefici
despit
complet
chemotherapi
treatment
month
prior
believ
unlik
patient
unrecogn
pid
none
patient
strong
identifi
pid
failur
thrive
intraven
antimicrobi
use
prior
patient
b
distant
famili
histori
defici
carri
mutat
investig
prior
start
chemotherapi
suggest
patient
b
c
expos
viral
infect
major
complic
final
patient
e
extens
genet
workup
exclud
common
scid
mutat
patient
c
normal
trec
assay
base
describ
histori
investig
conclud
secondari
immunodefici
produc
chemotherapi
studi
immun
reconstitut
children
receiv
chemotherapi
hematolog
malign
demonstr
children
total
lymphocyt
count
recov
within
total
count
normal
children
month
children
month
chemotherapi
initi
thought
total
recov
within
month
cessat
recent
studi
shown
delay
drop
may
take
month
fulli
recoveri
subset
shown
direct
relationship
intens
therapi
invers
relationship
invers
relationship
thought
recov
rapidli
pathway
normal
thymic
involut
begin
approxim
year
thymic
enlarg
post
chemotherapi
demonstr
pediatr
children
treat
requir
month
recov
count
month
greater
regardless
treatment
despit
prolong
impair
immun
function
sever
opportunist
infect
typic
appreci
cessat
chemotherapi
death
infect
recoveri
pattern
seen
patient
addit
cyclophosphamid
cytarabin
associ
deplet
earli
lineag
thu
affect
although
patient
treat
prior
cyclophosphamid
elimin
induct
patient
expos
cumul
cyclophosphamid
dose
least
doubl
protocol
use
older
possibl
higher
dose
cyclophosphamid
cytarabin
exposur
contribut
poor
recoveri
none
studi
examin
immun
reconstitut
chemotherapi
focus
infant
thu
pattern
immun
recoveri
compar
older
children
unknown
patient
sever
defici
count
less
despit
mildli
lymphopen
patient
underw
autopsi
found
profound
thymic
involut
suggest
damag
thymu
like
contribut
poor
recoveri
patient
b
treat
previou
report
patient
hiv
recov
unfortun
despit
treatment
show
sign
recoveri
first
report
case
sever
persist
immunodefici
vari
deplet
secondari
infant
chemotherapi
children
may
benefit
preemptiv
aggress
infect
manag
andor
requir
therapi
assist
immun
reconstitut
hsct
howev
preval
complic
unknown
formal
evalu
identifi
abnorm
recoveri
consid
patient
infant
follow
modern
intens
chemotherapi
protocol
